PCVX — Vaxcyte, Inc.
Healthcare · ETF XLV · as of 2026-09-18
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Vaxcyte, Inc.
NMS
Healthcare · Biotechnology
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Price & today
$58.13
ATR(14) 2.21 (3.80%)
| Stock today | -3.71% |
| Sector ETF today | -0.25% |
| Residual (stock-specific) | -3.46% |
Sector correlation
| 20-day correlation with XLV | 0.36 |
| 60-day correlation with XLV | 0.41 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $59.50 |
| 20 EMA | $59.66 |
| 50 EMA | $58.52 |
| EMA stack | NEUTRAL |
| RSI(14) | 44.3 |
| 52-week high distance | -10.57% |
| 52-week low distance | +106.94% |
Signals
| Market F&G | 46.9 |
| Bull% | 12.2% |
| OVTLYR status | SELL (5d) |
| Sector rank | #305 |
| Next earnings | 2026-11-02 (TNS, 44d) |
MarketSmith metrics - our compute
RS Rating
34.6
ADR%
3.5
RMV (tight)
98.0
Ext (ATR>20EMA)
-0.7
Rel Vol
256.0%
U/D 50d
0.80
U/D 25d
0.80
Accum/Dist 25d
4 / 5
EPS YoY
-61.0%
LoD dist
51.0
Off 52w High
10.6%
Above 52w Low
88.2%
1W / 1M
-2.3 / -8.2
Avg $Vol 50d
62.0M
Mkt Cap (B)
8.4
Trend 8/8
no
Leads Group
YES
Sector XLV
+1.8% 1W
Base len (VCP)
20wk (9/7)
Coil (base shape)
85TVPX
not available: revenue(no EDGAR qtrs=1 fact)
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
-
Fwd P/E
-
PEG
-
Price/Book
2.9
Profit margin
0.0%
ROE
-25.6%
Debt/Equity
4.4
Rev growth
-
Analyst target
$109 (+88%)
Analyst rating
NONE
Institutional %
104.0%
Insider %
0.5%
Float %
91.6%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
57 / 147
Industry
Biotechnology
Float
132.3M
Float turnover 20d
0.9%
Avg $Vol 20d / 50d
74.7M / 62.0M
Days to cover
10.7
Short % float
10.0%
Institutional %
104.0%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Nov-24 | -0.83 | - | - | - |
| Feb-25 | -1.02 | - | - | - |
| May-25 | -1.04 | - | - | - |
| Aug-25 | -1.22 | - | - | - |
| Nov-25 | -1.56 | - | - | - |
| Feb-26 | -1.80 | - | - | - |
| May-26 | -2.30 | - | - | - |
| Aug-26 | -1.97 | - | - | - |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 17 · Vaxcyte (PCVX) Brings In Pharma Veterans As Its Big Test Nears Yahoo
- Sep 08 · Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing The Motley Fool
- Sep 08 · A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know The Motley Fool
- Sep 08 · Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm The Motley Fool
- Sep 08 · Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing Yahoo
- Sep 08 · A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know Yahoo
- Sep 08 · Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm Yahoo
- Sep 08 · Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm The Motley Fool